News

2020-07-23

NOVAVAX AND FUJIFILM DIOSYNTH BIOTECHNOLOGIES INITIATE LARGE SCALE MANUFACTURING OF COVID-19 VACCINE CANDIDATE

Novavax, Inc. and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.

2020-06-17

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

2020-06-08

Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines

2020-06-04

“READY TO SAVE THE WORLD” WITH MASS VACCINE MANUFACTURING

On the show, Chancellor Sharp interviewed Dr. Gerry Farrell, chief operating officer of FUJIFILM Diosynth Biotechnologies, Texas, based in College Station

2020-06-01

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

2020-05-07

Developing a Biomanufacturing Platform to Fill a Need

As a contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies’ scientists and engineers need to offer flexible solutions to changing customer requirements.

2020-04-09

Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S.

FUJIFILM Corporation announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.

2020-03-06